A second scan using prostate-specific membrane antigen positron emission tomography changed treatment plans for nearly half of patients with recurrent prostate cancer whose initial scan was negative, according to research published in the July issue of The Journal of Nuclear Medicine.
Here are four things to know:
- The prospective multicenter study included 210 patients from the Registry for Recurrent Prostate Cancer in Ontario who underwent more than one PSMA PET scan after their initial scan showed no detectable disease.
- A second scan identified disease in 56% of patients, leading to a change in management for nearly 50%.
- Researchers found repeat imaging was most likely to detect disease in patients with higher prostate-specific antigen levels and a PSA doubling time of less than 12 months. Disease identified on repeat imaging included local recurrence, locoregional disease, oligometastatic disease and extensive metastatic disease.
- The findings suggest repeat PSMA PET imaging may provide clinically meaningful information for patients with recurrent prostate cancer despite an initial negative scan, particularly when PSA levels continue to rise.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
